Charles River Laboratories International, Inc. (CRL) 10-Year Financial Performance & Capital Metrics

CRL • • Industrial / General

HealthcareDiagnostics & ResearchContract Research & Clinical Trial ServicesResearch Support Services

AboutCharles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.Show more

Revenue $4.05B -1.9%
EBITDA $589M -36.8%
Net Income $10M -97.8%
EPS (Diluted) 0.20 -97.8%
Gross Margin 32.88% -9.6%
EBITDA Margin 14.55% -35.5%
Operating Margin 5.61% -62.4%
Net Margin 0.25% -97.8%
ROE 0.29% -98.0%
ROIC 2.73% -63.6%
Debt/Equity 0.78 -7.3%
Interest Coverage 1.80 -60.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)
✓High quality earnings: Operating CF exceeds net income
✓Trading near 52-week high

✗Weaknesses

✗Profits declining 47.2% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.05%

5Y9.09%

3Y4.59%

TTM-0.92%

Profit (Net Income) CAGR

10Y-22.2%

5Y-47.25%

3Y-70.25%

TTM-120.21%

EPS CAGR

10Y-22.8%

5Y-47.62%

3Y-70.26%

TTM-119.52%

ROCE

10Y Avg10.13%

5Y Avg8.78%

3Y Avg7.59%

Latest3.33%

Peer Comparison

Research Support Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRLCharles River Laboratories International, Inc.	11B	223.47	1117.35	-1.92%	-2.07%	-2.42%	4.56%	0.78
SHCSotera Health Company	5.5B	19.35	120.94	4.88%	4.82%	10.07%	0.82%	5.81
ISPCiSpecimen Inc.	4.22M	0.42	-0.02	-6.42%	-343.99%	-375.34%		0.09
NOTVInotiv, Inc.	19.59M	0.57	-0.27	4.54%	-13.38%	-50.45%		3.01
ACRSAclaris Therapeutics, Inc.	289.28M	2.67	-1.56	-40.09%	-9%	-117.97%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.36B	1.68B	1.86B	2.27B	2.62B	2.92B	3.54B	3.98B	4.13B	4.05B
Revenue Growth %	0.05%	0.23%	0.1%	0.22%	0.16%	0.12%	0.21%	0.12%	0.04%	-0.02%
Cost of Goods Sold+	832.21M	1.04B	1.16B	1.43B	1.66B	1.85B	2.21B	2.51B	2.63B	2.72B
COGS % of Revenue	0.61%	0.62%	0.62%	0.63%	0.63%	0.63%	0.62%	0.63%	0.64%	0.67%
Gross Profit+	531.09M	643.96M	700.92M	840.07M	958.31M	1.07B	1.33B	1.46B	1.5B	1.33B
Gross Margin %	0.39%	0.38%	0.38%	0.37%	0.37%	0.37%	0.38%	0.37%	0.36%	0.33%
Gross Profit Growth %	0.12%	0.21%	0.09%	0.2%	0.14%	0.12%	0.24%	0.1%	0.03%	-0.11%
Operating Expenses+	324.64M	406.41M	412.64M	508.68M	607.16M	640.81M	744.78M	811.68M	885.29M	1.1B
OpEx % of Revenue	0.24%	0.24%	0.22%	0.22%	0.23%	0.22%	0.21%	0.2%	0.21%	0.27%
Selling, General & Admin	300.41M	364.71M	371.27M	443.85M	517.62M	528.93M	619.92M	665.1M	747.86M	751M
SG&A % of Revenue	0.22%	0.22%	0.2%	0.2%	0.2%	0.18%	0.18%	0.17%	0.18%	0.19%
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	24.23M	41.7M	41.37M	64.83M	89.54M	111.88M	124.86M	146.58M	137.44M	353.47M
Operating Income+	206.45M	237.55M	288.28M	331.38M	351.15M	432.73M	589.86M	650.98M	617.26M	227.35M
Operating Margin %	0.15%	0.14%	0.16%	0.15%	0.13%	0.15%	0.17%	0.16%	0.15%	0.06%
Operating Income Growth %	0.16%	0.15%	0.21%	0.15%	0.06%	0.23%	0.36%	0.1%	-0.05%	-0.63%
EBITDA+	301.33M	364.21M	419.44M	493.16M	549.25M	667.65M	855.4M	954.85M	931.38M	589.09M
EBITDA Margin %	0.22%	0.22%	0.23%	0.22%	0.21%	0.23%	0.24%	0.24%	0.23%	0.15%
EBITDA Growth %	0.1%	0.21%	0.15%	0.18%	0.11%	0.22%	0.28%	0.12%	-0.02%	-0.37%
D&A (Non-Cash Add-back)	94.88M	126.66M	131.16M	161.78M	198.09M	234.92M	265.54M	303.87M	314.12M	361.74M
EBIT	210.5M	250.63M	326.73M	345.45M	364.97M	533.55M	554.62M	682.28M	717.99M	219.4M
Net Interest Income+	-14.03M	-26.39M	-29.09M	-62.96M	-59.36M	-85.6M	-73.26M	-58.51M	-131.51M	-117.71M
Interest Income	1.04M	1.31M	690K	812K	1.52M	834K	652K	780K	5.2M	8.57M
Interest Expense	15.07M	27.71M	29.78M	63.77M	60.88M	86.43M	73.91M	59.29M	136.71M	126.29M
Other Income/Expense	-11.02M	-14.63M	8.67M	-49.7M	-47.07M	14.38M	-109.15M	-27.99M	-35.98M	-134.23M
Pretax Income+	195.43M	222.92M	296.95M	281.68M	304.08M	447.11M	480.71M	622.99M	581.28M	93.11M
Pretax Margin %	0.14%	0.13%	0.16%	0.12%	0.12%	0.15%	0.14%	0.16%	0.14%	0.02%
Income Tax+	43.39M	66.83M	171.37M	54.46M	50.02M	81.81M	81.87M	130.38M	100.91M	67.82M
Effective Tax Rate %	0.76%	0.69%	0.42%	0.8%	0.83%	0.81%	0.81%	0.78%	0.82%	0.11%
Net Income+	149.31M	154.76M	123.36M	226.37M	252.02M	364.3M	390.98M	486.23M	474.62M	10.3M
Net Margin %	0.11%	0.09%	0.07%	0.1%	0.1%	0.12%	0.11%	0.12%	0.11%	0%
Net Income Growth %	0.18%	0.04%	-0.2%	0.84%	0.11%	0.45%	0.07%	0.24%	-0.02%	-0.98%
Net Income (Continuing)	152.04M	156.09M	125.59M	227.22M	254.06M	365.31M	398.84M	492.61M	480.37M	25.29M
Discontinued Operations	0	280K	0	1.51M	0	0	0	0	0	0
Minority Interest	32.5M	17.02M	18.94M	20.97M	31.89M	29.07M	57.17M	47.21M	62.12M	46.58M
EPS (Diluted)+	3.13	3.23	2.54	4.62	5.07	7.20	7.60	9.48	9.22	0.20
EPS Growth %	0.18%	0.03%	-0.21%	0.82%	0.1%	0.42%	0.06%	0.25%	-0.03%	-0.98%
EPS (Basic)	3.21	3.29	2.60	4.72	5.17	7.35	7.77	9.57	9.27	0.20
Diluted Shares Outstanding	47.63M	47.96M	48.56M	49.02M	49.69M	50.61M	51.42M	51.3M	51.45M	51.63M
Basic Shares Outstanding	46.5M	47.01M	47.48M	47.95M	48.73M	49.55M	50.29M	50.81M	51.23M	51.38M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	559.23M	656.83M	826.63M	897.84M	1.02B	1.2B	1.27B	1.44B	1.61B	1.4B
Cash & Short-Term Investments	117.95M	117.63M	163.79M	195.44M	238.96M	229.45M	246.3M	233.91M	276.77M	194.61M
Cash Only	117.95M	117.63M	163.79M	195.44M	238.01M	228.42M	245.24M	233.91M	276.77M	194.61M
Short-Term Investments	0	0	0	0	941K	1.02M	0	0	0	0
Accounts Receivable	270.07M	364.05M	430.02M	472.25M	514.03M	617.74M	650.38M	752.39M	780.38M	720.91M
Days Sales Outstanding	72.31	79.03	84.49	76.06	71.58	77.11	67.06	69.07	68.98	64.97
Inventory	93.73M	95.83M	114.96M	127.89M	160.66M	185.69M	199.15M	255.81M	380.26M	278.54M
Days Inventory Outstanding	41.11	33.72	36.28	32.73	35.26	36.63	32.96	37.15	52.84	37.4
Other Current Assets	149K	0	0	300K	731K	3.07M	0	107.58M	83.38M	105.8M
Total Non-Current Assets+	1.51B	2.05B	2.1B	2.96B	3.67B	4.29B	5.75B	6.16B	6.59B	6.13B
Property, Plant & Equipment	677.96M	755.83M	781.97M	932.88M	1.18B	1.3B	1.58B	1.86B	2.03B	2.02B
Fixed Asset Turnover	2.01x	2.22x	2.38x	2.43x	2.21x	2.24x	2.23x	2.14x	2.03x	2.01x
Goodwill	438.83M	787.52M	804.91M	1.25B	1.54B	1.81B	2.71B	2.85B	3.1B	2.85B
Intangible Assets	280.8M	394.45M	369.76M	610.89M	689.41M	787.6M	1.06B	955.27M	864.05M	723.4M
Long-Term Investments	32.73M	45.33M	71.1M	88.59M	122.98M	221.8M	201.35M	311.6M	243.81M	218.35M
Other Non-Current Assets	38.91M	43.1M	52.9M	55.17M	89.64M	130.82M	151.54M	148.28M	309.38M	278.23M
Total Assets+	2.07B	2.71B	2.93B	3.86B	4.69B	5.49B	7.02B	7.6B	8.2B	7.53B
Asset Turnover	0.66x	0.62x	0.63x	0.59x	0.56x	0.53x	0.50x	0.52x	0.50x	0.54x
Asset Growth %	0.1%	0.31%	0.08%	0.32%	0.22%	0.17%	0.28%	0.08%	0.08%	-0.08%
Total Current Liabilities+	311.76M	429.59M	463.5M	558.22M	710.18M	839.75M	1.03B	1.09B	1.06B	994.1M
Accounts Payable	36.67M	68.48M	77.84M	66.25M	111.5M	122.47M	198.13M	205.91M	168.94M	140.34M
Days Payables Outstanding	16.09	24.09	24.56	16.96	24.47	24.16	32.79	29.9	23.47	18.84
Short-Term Debt	17.03M	27.31M	31M	31.42M	35.55M	47.2M	101K	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	91.71M	86.97M	92.81M	181.18M	169.71M	217.5M	307.01M	401.65M	431.04M	373.43M
Current Ratio	1.79x	1.53x	1.78x	1.61x	1.44x	1.43x	1.23x	1.32x	1.52x	1.41x
Quick Ratio	1.49x	1.31x	1.54x	1.38x	1.21x	1.21x	1.04x	1.08x	1.16x	1.13x
Cash Conversion Cycle	97.33	88.65	96.21	91.84	82.37	89.58	67.22	76.31	98.34	83.53
Total Non-Current Liabilities+	991.17M	1.43B	1.4B	1.96B	2.32B	2.51B	3.4B	3.49B	3.48B	3.03B
Long-Term Debt	846M	1.21B	1.11B	1.64B	1.82B	1.9B	2.92B	2.71B	2.65B	2.24B
Capital Lease Obligations	31.76M	27.2M	27.88M	26.05M	143.78M	184.64M	252.97M	389.75M	419.23M	483.79M
Deferred Tax Liabilities	48.22M	55.72M	89.54M	143.63M	167.28M	217.03M	239.72M	215.58M	191.35M	106.96M
Other Non-Current Liabilities	65.19M	137.81M	166.93M	118.65M	161.95M	185.74M	-30.69M	174.82M	223.19M	195.21M
Total Liabilities	1.3B	1.86B	1.87B	2.52B	3.03B	3.35B	4.43B	4.58B	4.54B	4.02B
Total Debt+	863.03M	1.24B	1.15B	1.7B	2.02B	2.16B	3.21B	3.1B	3.07B	2.72B
Net Debt	745.08M	1.12B	981.31M	1.5B	1.79B	1.93B	2.96B	2.86B	2.79B	2.53B
Debt / Equity	1.13x	1.45x	1.08x	1.27x	1.22x	1.01x	1.24x	1.02x	0.84x	0.78x
Debt / EBITDA	2.86x	3.39x	2.73x	3.44x	3.69x	3.24x	3.75x	3.24x	3.29x	4.62x
Net Debt / EBITDA	2.47x	3.07x	2.34x	3.05x	3.25x	2.89x	3.47x	3.00x	3.00x	4.29x
Interest Coverage	13.70x	8.57x	9.68x	5.20x	5.77x	5.01x	7.98x	10.98x	4.52x	1.80x
Total Equity+	765.56M	853.78M	1.06B	1.34B	1.67B	2.14B	2.59B	3.02B	3.66B	3.51B
Equity Growth %	0.09%	0.12%	0.25%	0.26%	0.25%	0.29%	0.21%	0.17%	0.21%	-0.04%
Book Value per Share	16.07	17.80	21.91	27.30	33.54	42.36	50.40	58.94	71.12	67.95
Total Shareholders' Equity	733.07M	836.77M	1.05B	1.32B	1.63B	2.11B	2.53B	2.98B	3.6B	3.46B
Common Stock	855K	863K	875K	482K	489K	498K	505K	509K	513K	511K
Retained Earnings	10.54M	165.3M	288.66M	42.1M	280.33M	625.41M	980.75M	1.43B	1.89B	1.81B
Treasury Stock	-1.54B	-1.55B	-1.66B	-55K	0	0	0	0	0	0
Accumulated OCI	-135.55M	-253.76M	-144.73M	-172.7M	-178.02M	-138.87M	-164.74M	-262.06M	-196.43M	-317.35M
Minority Interest	32.5M	17.02M	18.94M	20.97M	31.89M	29.07M	57.17M	47.21M	62.12M	46.58M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	286.36M	298.32M	316.26M	441.14M	480.94M	546.58M	760.8M	619.64M	683.9M	734.58M
Operating CF Margin %	0.21%	0.18%	0.17%	0.19%	0.18%	0.19%	0.21%	0.16%	0.17%	0.18%
Operating CF Growth %	0.14%	0.04%	0.06%	0.39%	0.09%	0.14%	0.39%	-0.19%	0.1%	0.07%
Net Income	152.04M	156.09M	125.59M	227.22M	254.06M	365.31M	398.84M	492.61M	480.37M	25.29M
Depreciation & Amortization	94.88M	126.66M	131.16M	161.78M	198.09M	234.92M	265.54M	303.87M	314.12M	361.74M
Stock-Based Compensation	40.12M	43.64M	44M	47.35M	57.27M	56.34M	71.47M	73.62M	72.05M	69.89M
Deferred Taxes	2.69M	1.95M	28.25M	-9.7M	-21.89M	-133K	-24.01M	-35.88M	-50.9M	-67.43M
Other Non-Cash Items	-12.99M	6K	-18.68M	-315K	-12.78M	-83.59M	6.01M	-62.02M	-29.36M	375.41M
Working Capital Changes	9.62M	-30.02M	5.94M	14.81M	6.18M	-26.27M	42.94M	-152.55M	-102.38M	-30.33M
Change in Receivables	-16.96M	-52.78M	-48.28M	-21.2M	-8.32M	-85.63M	-26.63M	-150.57M	-33.43M	21.61M
Change in Inventory	3.36M	-4.02M	-17.84M	-13.34M	-21.4M	-18.38M	-25.16M	-78.52M	-62.3M	16.8M
Change in Payables	1.17M	22.08M	34K	-12.73M	29.77M	748K	44.9M	-2.65M	-20.43M	-14.27M
Cash from Investing+	-320.29M	-686.37M	-72.59M	-955M	-681.5M	-601.54M	-1.44B	-607.92M	-563.15M	-245.09M
Capital Expenditures	-63.25M	-55.29M	-82.43M	-140.05M	-140.51M	-166.56M	-228.77M	-324.73M	-318.53M	-232.97M
CapEx % of Revenue	0.05%	0.03%	0.04%	0.06%	0.05%	0.06%	0.06%	0.08%	0.08%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.22M	3.69M	-516K	-805K	-3.89M	-1.06M	264K	-9.35M	-2.29M	4.55M
Cash from Financing+	4.55M	390.73M	-208.48M	558.06M	231.94M	47.25M	672.6M	-42.4M	-85.52M	-550.93M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	7.48M	-8.23M	34.01M	17.88M	16.15M	40.64M	43.32M	-23.54M	13.96M	-19.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	223.11M	243.03M	233.83M	301.09M	340.42M	380.01M	532.03M	294.91M	365.37M	501.61M
FCF Margin %	0.16%	0.14%	0.13%	0.13%	0.13%	0.13%	0.15%	0.07%	0.09%	0.12%
FCF Growth %	0.15%	0.09%	-0.04%	0.29%	0.13%	0.12%	0.4%	-0.45%	0.24%	0.37%
FCF per Share	4.68	5.07	4.81	6.14	6.85	7.51	10.35	5.75	7.10	9.72
FCF Conversion (FCF/Net Income)	1.92x	1.93x	2.56x	1.95x	1.91x	1.50x	1.95x	1.27x	1.44x	71.34x
Interest Paid	11.1M	22.76M	27.42M	47.54M	67.81M	72.46M	70.78M	100.75M	132.1M	123.45M
Taxes Paid	24.44M	42.87M	60.38M	67.6M	54.06M	60.06M	75.44M	75.91M	90.37M	126.06M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	20.32%	19.11%	12.86%	18.85%	16.77%	19.12%	16.51%	17.32%	14.21%	0.29%
Return on Invested Capital (ROIC)	10.93%	10.23%	10.77%	10.17%	8.37%	8.62%	9.19%	8.54%	7.51%	2.73%
Gross Margin	38.96%	38.3%	37.73%	37.07%	36.56%	36.72%	37.7%	36.79%	36.39%	32.88%
Net Margin	10.95%	9.2%	6.64%	9.99%	9.61%	12.46%	11.04%	12.23%	11.49%	0.25%
Debt / Equity	1.13x	1.45x	1.08x	1.27x	1.22x	1.01x	1.24x	1.02x	0.84x	0.78x
Interest Coverage	13.70x	8.57x	9.68x	5.20x	5.77x	5.01x	7.98x	10.98x	4.52x	1.80x
FCF Conversion	1.92x	1.93x	2.56x	1.95x	1.91x	1.50x	1.95x	1.27x	1.44x	71.34x
Revenue Growth	5.06%	23.34%	10.48%	21.99%	15.67%	11.55%	21.08%	12.31%	3.86%	-1.92%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Discovery and Safety Assessment	612.17M	836.59M	980.02M	1.32B	1.62B	1.84B	2.11B	2.45B	2.62B	2.45B
Discovery and Safety Assessment Growth	-	36.66%	17.14%	34.37%	22.94%	13.49%	14.68%	16.14%	6.88%	-6.28%
Research Models and Services	473.23M	494.04M	493.62M	519.68M	537.09M	571.15M	690.44M	739.17M	792.34M	829.38M
Research Models and Services Growth	-	4.40%	-0.09%	5.28%	3.35%	6.34%	20.88%	7.06%	7.19%	4.67%
Manufacturing Support	277.9M	350.8M	383.96M	429.56M	465.14M	515.35M	742.49M	789.57M	721.44M	769.33M
Manufacturing Support Growth	-	26.23%	9.45%	11.88%	8.28%	10.79%	44.07%	6.34%	-8.63%	6.64%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	659.47M	850.42M	959.26M	1.27B	1.47B	1.63B	1.93B	2.34B	2.35B	2.24B
UNITED STATES Growth	-	28.96%	12.80%	32.15%	16.05%	10.61%	18.88%	21.08%	0.23%	-4.58%
Europe	435.49M	520.94M	569.81M	643.96M	726.42M	829.31M	1.04B	1.03B	1.08B	1.08B
Europe Growth	-	19.62%	9.38%	13.01%	12.81%	14.16%	24.98%	-0.42%	4.34%	0.11%
CANADA	172.35M	194.21M	200.34M	206.38M	271.99M	306.26M	339.1M	398.98M	487.31M	482.09M
CANADA Growth	-	12.68%	3.16%	3.01%	31.79%	12.60%	10.72%	17.66%	22.14%	-1.07%
Asia Pacific	-	-	-	-	-	-	222.9M	192.84M	200.83M	196.95M
Asia Pacific Growth	-	-	-	-	-	-	-	-13.49%	4.15%	-1.93%
JAPAN	40.52M	46.83M	126.46M	142.5M	146.22M	155.09M	-	-	-	-
JAPAN Growth	-	15.57%	170.05%	12.68%	2.61%	6.06%	-	-	-	-
Other Non U.S.	-	69.03M	-	-	-	-	-	-	-	-
Other Non U.S. Growth	-	-	-	-	-	-	-	-	-	-
Asia	55.48M	-	-	-	-	-	-	-	-	-
Asia Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Charles River Laboratories International, Inc. (CRL) reported $4.02B in revenue for fiscal year 2024. This represents a 252% increase from $1.14B in 2011.

Charles River Laboratories International, Inc. (CRL) saw revenue decline by 1.9% over the past year.

Charles River Laboratories International, Inc. (CRL) reported a net loss of $83.5M for fiscal year 2024.

Dividend & Returns

Charles River Laboratories International, Inc. (CRL) has a return on equity (ROE) of 0.3%. This is below average, suggesting room for improvement.

Charles River Laboratories International, Inc. (CRL) generated $543.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...